Department of Internal Medicine I, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Department of Internal Medicine I, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Int J Cardiol. 2020 Jun 15;309:48-54. doi: 10.1016/j.ijcard.2020.03.021. Epub 2020 Mar 19.
Data on the prevalence of depression and anxiety in elderly cardiovascular disease patients are limited and there are only few studies focussing on treatment effects. Thus, the current study aimed to analyse elderly patients suffering from aortic stenosis (AS) and undergoing transcatheter aortic valve replacement (TAVR) with respect to both, prevalence rates before TAVR and dynamics in the clinical course.
The study included 140 AS patients undergoing TAVR (77.8 ± 7.7 years, 42.9% male, mean STS-Score 4.4 ± 2.2). Detailed clinical, laboratory and functional analysis was performed. In addition, quality of life (EQ-5D, EQ VAS), clinical frailty (CFS) and anxiety/depression (HADS-D), was assessed at baseline, 6 weeks, 6 months and 12 months after TAVR.
Before TAVR, HADS-D revealed ≥8 points for anxiety and/or depression in 54 patients (38.6%), depression in 33 patients (23.6%) and for anxiety in 40 patients (28.6%). In the group showing HADS-D ≥8 points for anxiety, there was an improvement already 6 weeks after TAVR for anxiety (p < 0.05) but not for depression. In the group showing HADS-D ≥8 points for depression, there was a significant improvement at the 6 weeks' follow-up for both, depression (p < 0.001) and anxiety (p = 0.012) remaining stable for depression but not for anxiety until 12 months after TAVR.
TAVR leads to reductions of depression and anxiety in patients showing pathologic baseline values in HADS-D. There were no associations between pre-existing depression and anxiety with long-term mortality in our study.
关于老年心血管疾病患者中抑郁和焦虑的患病率数据有限,并且只有少数研究关注治疗效果。因此,目前的研究旨在分析患有主动脉瓣狭窄(AS)并接受经导管主动脉瓣置换术(TAVR)的老年患者,既要分析他们在 TAVR 之前的患病率,也要分析他们在临床过程中的动态变化。
这项研究纳入了 140 名接受 TAVR 的 AS 患者(77.8±7.7 岁,42.9%为男性,平均 STS 评分 4.4±2.2)。对他们进行了详细的临床、实验室和功能分析。此外,在 TAVR 之前、6 周、6 个月和 12 个月时,还评估了他们的生活质量(EQ-5D、EQ VAS)、临床虚弱(CFS)和焦虑/抑郁(HADS-D)。
在 TAVR 之前,HADS-D 显示有 54 名患者(38.6%)存在焦虑和/或抑郁≥8 分,33 名患者(23.6%)存在抑郁,40 名患者(28.6%)存在焦虑。在 HADS-D 显示焦虑≥8 分的患者中,在 TAVR 后 6 周时,焦虑就已经有所改善(p<0.05),但抑郁没有改善。在 HADS-D 显示抑郁≥8 分的患者中,在 6 周的随访中,抑郁和焦虑都有显著改善(p<0.001 和 p=0.012),但在 12 个月后,抑郁仍然稳定,而焦虑则没有改善。
TAVR 可降低 HADS-D 显示有病理基线值的患者的抑郁和焦虑程度。在我们的研究中,抑郁和焦虑与长期死亡率之间没有关联。